TSND-201 produced statistically significant placebo-adjusted improvements in PTSD severity.
The executive order dramatically affects research priorities, regulatory momentum, investment, and adoption.
Read morePSYCHOTHERAPY FOR ADOLESCENTS, CHildren AND ADULTS
TSND-201 produced statistically significant placebo-adjusted improvements in PTSD severity.
The executive order dramatically affects research priorities, regulatory momentum, investment, and adoption.
Read moreBig news for MDMA-assisted therapy. Here are a couple takes on it:
https://themicrodose.substack.com/p/breaking-news-federal-regulators
https://psychedelicinvest.com/fda-denies-lykos-and-requests-another-trial/
The Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted overwhelmingly to reject MDMA-assisted therapy in the treatment of post traumatic stress disorder, or PTSD.
The FDA will issue its final decision on the matter in mid-August but in the majority of cases, the federal agency’s decisions align with the vote of the independent panelists on advisory committees.
Read moreTwo articles cover this recent update.
npr: Misconduct claims may derail MDMA psychedelic treatment for PTSD
Axios: Landmark review spotlights challenge of judging psychedelic therapies
Read moreMDMA therapy for PTSD could become a new treatment option for millions of people living with trauma. The clinical evidence is growing.
Read moreHere a UC researcher discusses how psychedelics show promise for treating PTSD and anxiety, but risks remain.
Read moreHere’s the official statement from MAPS!
The results confirmed findings from MAPP1; no serious adverse events were observed among the participants
In a first for psychedelic-assisted therapy trials, more than half of MAPP2 participants identify as people of color
Veterans are turning to psychedelic treatments for PTSD healing.
Read moreResearchers are looking at how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.
Read more